Waterhouse, David
Horn, Leora
Reynolds, Craig
Spigel, David
Chandler, Jason
Mekhail, Tarek
Mohamed, Mohamed
Creelan, Ben
Blankstein, Kenneth B.
Nikolinakos, Petros
McCleod, Michael J.
Li, Ang
Oukessou, Abderrahim
Agrawal, Shruti
Aanur, Nivedita
Funding for this research was provided by:
Bristol-Myers Squibb
Article History
Received: 9 January 2018
Accepted: 23 January 2018
First Online: 13 February 2018
Compliance with ethical standards
:
: Dr Waterhouse has participated in speakers’ bureau for Genentech, Eli Lilly, Celgene, and Bristol-Myers Squibb, where he also served in a consulting and/or an advisory role. Dr Horn has served in a consulting and/or an advisory role for Genentech, Merck, Bristol-Myers Squibb, Boehringer Ingelheim, XCovery, and Bayer; she received research funding from aSuperscript removed Pharmaceutical; and she disclosed a financial relationship with Biodesix. Dr Reynolds has reported stock or ownership interest in Gilead; he has served in a consulting and/or an advisory role for, and received travel, accommodations, expenses, and honoraria from, Eli Lilly, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, and AstraZeneca; he has participated in a speakers’ bureau for Eli Lilly, Boehringer Ingelheim, Genentech, and AstraZeneca. Dr Spigel has served in a consulting and/or an advisory role for Novartis and Genentech; he has received travel, accommodations, and expenses from Novartis, Genentech, and Pfizer. Dr Chandler has served in a consulting and/or an advisory role for, and received travel, accommodations, and expenses from, Bristol-Myers Squibb, Janssen, and Caris Life Sciences. Dr Mekhail has participated in a speakers’ bureau for, and received research funding and honoraria from, Bristol-Myers Squibb. Dr Mohamed has served in a consulting and/or an advisory role for, and has participated in a speakers’ bureau for, Eli Lilly, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, and Merck. Dr Creelan has participated in a speakers’ bureau for, and has received travel, accommodations, and expenses from, Bristol-Myers Squibb and AstraZeneca; he has received research funding and honoraria from Boehringer Ingelheim. Dr. Blankstein has no financial relationships to disclose. Dr Nikolinakos has served in a consulting and/or an advisory role for Eli Lilly, Boehringer Ingelheim, and Exelixis; he has participated in a speakers’ bureau for Boehringer Ingelheim. Dr McCleod has no financial relationships to disclose. Mr Li has been employed by and owns stock in Bristol-Myers Squibb Company. Dr Oukessou has been employed by and owns stock in Bristol-Myers Squibb Company. Dr Agrawal has been employed by and owns stock in Bristol-Myers Squibb Company. Dr Aanur has been employed by and owns stock in Bristol-Myers Squibb Company. No others disclosures were reported.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.
: Informed consent was obtained from all individual participants included in the study.